Home › Research › Biomarkers
Effects of Low‐Intensity Ultrasound on Amyloid‐ β Clearance in Early‐Stage Alzheimer′s Disease: A Potential Role of Glymphatic Activity
Sang Won Jo, Bo-yong Park, Roh‐Eul Yoo, Seung Hong Choi, Sooyeon Ji, Tae Young Park, Hyungmin Kim, Seongbeom Park et al.. Acta Neurologica Scandinavica, 2026-01-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Objective Alzheimer′s disease (AD) involves impaired clearance of metabolic waste, including amyloid‐ β , potentially related to glymphatic dysfunction. Low‐intensity ultrasound (LIUS) may facilitate solute clearance in the brain. This pilot study examined whether LIUS affects amyloid‐ β deposition and cognitive performance in early‐stage AD, and whether MRI‐derived changes in putative glymphatic activity could represent a possible underlying mechanism. Methods This prospective pilot study (September 2022–February 2023) enrolled 10 amyloid‐positive participants who underwent 4 weeks of LIUS treatment, including five apolipoprotein E4 (APOE4) carriers and five noncarriers. LIUS treatment involved sessions over 4 weeks. Magnetic resonance imaging (MRI) and amyloid PET scans were used to quantitatively analyze glymphatic activity, blood–brain barrier (BBB) integrity, microbleed occurrence, and amyloid deposition changes. Cognitive changes were assessed using neuropsychological tests. Results All participants completed treatment without any significant adverse events. Neuropsychological testing demonstrated cognitive function improvements. Amyloid‐ β deposition decreased mainly in APOE4 carriers following LIUS. In addition, post‐LIUS, the cerebral cortex showed increased putative glymphatic activity, although statistical significance was not maintained after multiple‐comparison correction. No significant changes were observed in BBB integrity, microbleed occurrence, or brain volume. Conclusion LIUS was safe and demonstrated both cognitive improvement and reduced amyloid deposition in early‐stage AD. These effects may reflect several biological actions of LIUS, including the possibility of glymphatic enhancement. Further studies with larger cohorts and appropriate control groups are warranted to confirm these findings and draw more definitive conclusions. Trial Registration Clinicaltrial.gov identifier: NCT05633095
What this study adds
Evidence grade: Low
In this small pilot study of 10 people with early-stage Alzheimer's, four weeks of low-intensity ultrasound was safe and was followed by improved cognitive test scores and reduced amyloid buildup, mainly in APOE4 carriers. However, this was a preliminary study without a control group, and the researchers say larger studies with control groups are needed to confirm the findings.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jo, S. W., Park, B.-y., Yoo, R., Choi, S. H., Ji, S., Park, T. Y., et al. (2026). Effects of Low‐Intensity Ultrasound on Amyloid‐ β Clearance in Early‐Stage Alzheimer′s Disease: A Potential Role of Glymphatic Activity. Acta Neurologica Scandinavica. https://doi.org/10.1155/ane/1538313
Vancouver
Jo SW, Park B.-y, Yoo R, Choi SH, Ji S, Park TY, et al. Effects of Low‐Intensity Ultrasound on Amyloid‐ β Clearance in Early‐Stage Alzheimer′s Disease: A Potential Role of Glymphatic Activity. Acta Neurologica Scandinavica. 2026. doi:10.1155/ane/1538313.
BibTeX
@article{jo2026-c42da504,
author = {Jo, Sang Won and Park, Bo-yong and Yoo, Roh‐Eul and Choi, Seung Hong and Ji, Sooyeon and Park, Tae Young and Kim, Hyungmin and Park, Seongbeom and others},
title = {{Effects of Low‐Intensity Ultrasound on Amyloid‐ β Clearance in Early‐Stage Alzheimer′s Disease: A Potential Role of Glymphatic Activity}},
journal = {Acta Neurologica Scandinavica},
year = {2026},
doi = {10.1155/ane/1538313},
url = {https://doi.org/10.1155/ane/1538313}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results All participants completed treatment without any significant adverse events.
- Neuropsychological testing demonstrated cognitive function improvements.
- No significant changes were observed in BBB integrity, microbleed occurrence, or brain volume.
- Conclusion LIUS was safe and demonstrated both cognitive improvement and reduced amyloid deposition in early‐stage AD.
- Further studies with larger cohorts and appropriate control groups are warranted to confirm these findings and draw more definitive conclusions.
Why it matters
In this small pilot study of 10 people with early-stage Alzheimer's, four weeks of low-intensity ultrasound was safe and was followed by improved cognitive test scores and reduced amyloid buildup, mainly in APOE4 carriers. However, this was a preliminary study without a control group, and the researchers say larger studies with control groups are needed to confirm the findings.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 40/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Acta Neurologica Scandinavica) |
| Journal's citation record | 2 / 4 | Acta Neurologica Scandinavica: journal h-index 160 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 3 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 4 / 6 | Cited 12.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Jaeho Kim: h-index 15 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Seoul National University: institution h-index 1,053 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 11 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Total | 40 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Biomarkers from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.